Skip to main content
Fig. 5 | Biomarker Research

Fig. 5

From: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma

Fig. 5

PI3K/AKT and CDK4/6 pathway dual inhibition demonstrate efficacy in iCCA.

A, Representative histograms depicting cell cycle profiles of iCCA cell lines on treatment with palbociclib (3000 nM), PF-04691502 (500 nM), the combination or with DMSO control for 48 h.

B-C, Immunofluorescence staining assay of iCCA cells treated with a single agent (PF-04691502 or palbociclib) or a combination of both compounds at a fixed ratio (1:1).

D-E, Western blot analysis of genes involved in PI3K/Akt pathway, cell cycle-related proteins and stemness biomarkers in iCCA cell lines treated with a single agent (PF-04691502 or palbociclib) or a combination of both compounds at a fixed ratio (1:1).

*p < 0.05; **p < 0.01; ***p < 0.001; Scale bar: 200 μm

Back to article page